Subgroup | GC culture | NAAT positive | NAAT negative | Total |
Men with urethral symptoms | Urethra | |||
Positive | 118 | 2 | 120 | |
Negative | 32 | 0 | 32 | |
Total | 150 | 2 | 152 | |
AC2 sensitivity 99% (150/152) (95% CI 95% to 100%) | ||||
Culture sensitivity 79% (120/152) (95% CI 71% to 85%) | ||||
Men without urethral symptoms | Urethra | |||
Positive | 4 | 1 | 5 | |
Negative | 12 | 0 | 12 | |
Total | 16 | 1 | 17 | |
AC2 sensitivity 94% (16/17) (95% CI 69% to 100%) | ||||
Culture sensitivity 29% (5/17) (95% CI 11% to 56%) | ||||
Men with rectal symptoms | Rectal | |||
Positive | 6 | 0 | 6 | |
Negative | 4 | 0 | 4 | |
Total | 10 | 0 | 10 | |
AC2 sensitivity 100% (10/10) (95% CI 66% to 100%) | ||||
Culture sensitivity 60% (6/10) (95% CI 27% to 86%) | ||||
Men without rectal symptoms | Rectal | |||
Positive | 6 | 1 | 7 | |
Negative | 6 | 0 | 6 | |
Total | 12 | 1 | 13 | |
AC2 sensitivity 92% (12/13) (95% CI 62% to 100%) | ||||
Culture sensitivity 54% (7/13) (95% CI 26% to 80%) | ||||
Women with vulvovaginal symptoms | Cervical | |||
Positive | 25 | 0 | 25 | |
Negative | 22 | 0 | 22 | |
Total | 47 | 0 | 47 | |
AC2 sensitivity 100% (47/47) (95% CI 95% to 100%) | ||||
Culture sensitivity 53% (25/47) (95% CI 38% to 68%) | ||||
Women without vulvovaginal symptoms | Cervical | |||
Positive | 15 | 0 | 15 | |
Negative | 17 | 0 | 17 | |
Total | 32 | 0 | 32 | |
AC2 sensitivity 100% (32/32) (95% CI 87% to 100%) | ||||
Culture sensitivity 47% (15/32) (95% CI 30% to 65%) |
NAAT, nucleic acid amplification tests.